Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Shares in Wegovy-maker Novo Nordisk pop 6% after GLP-1 pill approval
03:02am, Tuesday, 23'rd Dec 2025
The FDA on Monday approved the first-ever GLP-1 pill from Novo Nordisk. The approval gives the Danish pharma giant a head start against U.S. rival Eli Lilly.
Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug
06:44pm, Monday, 22'nd Dec 2025
The FDA approved Novo Nordisk's Wegovy pill as the first oral GLP-1 treatment for weight loss. The Danish drug giant jumped overnight.
FDA approves first GLP-1 pill for obesity from Novo Nordisk
06:09pm, Monday, 22'nd Dec 2025
FDA approves first GLP-1 pill for obesity from Novo Nordisk
The FDA has approved the first GLP-1 pill for weight loss, clearing a tablet from Novo Nordisk
06:05pm, Monday, 22'nd Dec 2025
Novo Nordisk said it plans to start selling the new pill in the U.S. soon after the new year, with a cash price of $149 a month for the starting dose.
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development
07:30am, Thursday, 18'th Dec 2025
No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telo
In ATTAIN-MAINTAIN, orforglipron achieved the primary and all key secondary endpoints for weight maintenance vs. placebo at 52 weeks following weight loss on Wegovy or Zepbound Participants who switch
Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era
09:05am, Tuesday, 16'th Dec 2025
A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalised nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss g
Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era
08:55am, Tuesday, 16'th Dec 2025
A redesigned Weight Watchers experience pairs GLP-1 prescriptions with personalized nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and
Where Will Eli Lilly Be in 10 Years?
05:15am, Tuesday, 16'th Dec 2025
Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). The company overtook early GLP-1 leader Novo Nordisk.
Can Intuitive Surgical Weather GLP-1 Drag on Bariatric Surgery?
09:51am, Thursday, 11'th Dec 2025
Intuitive Surgical grapples with a GLP-1-driven bariatric slump but leans on strong general surgery gains and rising da Vinci 5 adoption.
Structure Therapeutics: Phase 2b Puts Aleniglipron In The Oral GLP-1 Top Tier (Rating Upgrade)
08:30am, Tuesday, 09'th Dec 2025
Structure Therapeutics (GPCR) delivered robust Phase 2b results for aleniglipron, surpassing key efficacy and tolerability thresholds for oral GLP-1 therapies. GPCR now appears competitive with top or
Lilly's GLP-1 Surge Dwarfs Abbott's Steady Device Growth With 54% Revenue Jump
08:21am, Monday, 08'th Dec 2025
Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets.
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation
- ASC30 once-daily tablets showed statistically significant and clinically meaningful dose-dependent placebo-adjusted mean body weight reductions with no observed plateau for weight loss. - ASC30
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met
